Abstract
Introduction In the last decade, there is an increasing mortality rate among patients diagnosed with prostate cancer (PCa) in West Africa. To identify the causes of the high mortality rate, this study analyzed the occurrence of high-grade tumours and the presence of BRCA2 mutation. It also assessed the systemic inflammatory indices as prognostic tools in low-resource settings.
Methods This study included 72 cases of PCa diagnosed from Jan. 2017 to Dec. 2020. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelets-neutrophils-to-lymphocytes ratio (PNLR), and neutrophils-to-lymphocytes platelets ratio (NLPR) were assessed and analyzed accordingly. Significance was set at p< 0.05.
Results The prevalence of Gleason grades (G) 1 to 5 was 9.3%, 16.3%, 16.3%, 25.6, and 32.6%, respectively. There was a high frequency of BRCA2 mutation (58.3%) and the frequency was higher among patients with G4/5 tumours (59.5%) than in patients with G1-G3 tumours (46.7%) at p= 0.347. A high frequency of G4/5 tumours was observed among patients within the age group of 50-59 years (n= 7/8; 87.5%) and patients with castration-resistant PCa (n= 12/17; 70.6%). The pre-treatment PLR and calcium concentration were higher among patients with G4/5 tumours compared to patients with G1-G3 tumours (p= 0.046 and < 0.001, respectively.) There were direct relationships between BRCA2 expression and age (p= 0.019), tumour grade and calcium (p= 0.000), BRCA2 and calcium expression (p= 0.027), unemployment and G4/5 (p< 0.001), and education status and G4/5 (p= 0.020). The pretreatment NLR and NLPR were 2.0 and 4.7 times higher in in-hospital deaths than in stable discharges at p= 0.005 and 0.001, respectively.
Conclusion This study revealed high frequencies of BRCA2 mutation and high-grade PCa in Southern Nigeria. It also suggests that pre-treatment PLR could be used to identify patients with G4/5 while pretreatment NLR and NLPR could be used to predict treatment outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nnamdi Azikiwe University Teaching Hospital Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors